Pharmacological monitoring of mycophenolic acid in blood in children with nephrotic syndrome

Idiopathic nephrotic syndrome in children is the most common glomerular disease in pediatric practice and frequently requires long-term immunosuppressive therapy because of steroid dependence and frequent relapses. Mycophenolate mofetil has emerged as a preferred steroid-sparing agent in international guidelines due to its favorable safety profile and proven efficacy in reducing relapse rates in steroid-dependent and frequently relapsing nephrotic syndrome in children. Its active metabolite, mycophenolic acid, exhibits marked interindividual pharmacokinetic variability influenced by age, serum albumin, kidney and liver function, concomitant therapies, and genetic factors, which underpins the need for therapeutic drug monitoring. This narrative review summarizes current evidence on the pharmacokinetics and pharmacodynamics of mycophenolic acid in pediatric nephrotic syndrome, focusing on target exposure parameters such as area under the concentration–time curve (AUC) and trough levels (C0) and their association with clinical efficacy and relapse risk. Particular attention is given to limited sampling strategies enabling reliable estimation of mycophenolic acid exposure from a small number of timed blood samples, as well as to population pharmacokinetic modeling as tools to individualize dosing in clinical practice. The potential role of inosine monophosphate dehydrogenase activity as a pharmacodynamic biomarker is discussed, and key gaps are highlighted, including the need for prospective trials to define optimal target exposure ranges for mycophenolic acid in children with steroid-dependent and frequently relapsing nephrotic syndrome.

1. Trautmann A., Boyer O., Hodson E., Bagga A., Gipson D.S., Samuel S., et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol. 2023;38(3):877– 919. DOI: 10-1007/s00467-022-05739-3.

2. Eddy A.A., Symons J.M. Nephrotic syndrome in childhood. Lancet. 2003;362(9384):629–639. DOI: 10-1016/S01406736(03)14184-0.

3. Dossier C., Lapidus N., Bayer F., Sellier-Leclerc A-L., Boyer O., de Pontual L., et al. Epidemiology of idiopathic nephrotic syndrome in children: endemic or epidemic? Pediatr Nephrol. 2016;31(12):2299–2308. DOI: 10-1007/s00467-016-3509-z.

4. Rovin B.H., Adler S.G., Barratt J., Bridoux F., Burdge K.A, Chan T.M., et al. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney International. 2021;100(4):753–779. DOI: 10-1016/j.kint.2021.05.015.

5. Floege J., Gibson K.L., Vivarelli M., Liew A., Radhakrishnan J., Rovin B.H. KDIGO 2025 Clinical Practice Guideline for the Management of Nephrotic Syndrome in Children. Kidney International. 2025;107(5):S241–S289. DOI: 10-1016/j.kint.2024.11.007.

6. Nourbakhsh N., Mak R. Steroid-resistant nephrotic syndrome: past and current perspectives. PHMT. 2017; 8: 29–37. DOI: 10-2147/PHMT.S100803.

7. Hahn D., Samuel S.M., Willis N.S, Craig J.C., Hodson E.M. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database of Systematic Reviews. 2020, DOI: 101002/14651858.CD001533.pub6.

8. Ehren R., Benz M.R., Brinkkötter P.T., Dötsch J., Eberl W.R., Gellermann J., et al. Pediatric idiopathic steroid-sensitive nephrotic syndrome: diagnosis and therapy — short version of the updated German best practice guideline (S2e) — AWMF register no. 166-001, 6/2020, Pediatr Nephrol. 2021;36(10):2971– 2985. DOI: 10-1007/s00467-021-05135-3.

9. Karunamoorthy S., Thanigachalam D., Jeyachandran D., Ramanathan S., Natarajan G., Thoppalan B. The safety and efficacy of mycophenolate mofetil in children and adolescents with steroid-dependent nephrotic syndrome: a single-centre study. Clin Kidney J. 2019;13(2):179–183. DOI: 10-1093/ckj/sfz061.

10. Aldakheel D.A., Alamir A., Almarshad K.K., Alsafwani Z.A., Alshaer R.A., Alzulfah A.T., et al. Retrospective Cross-Sectional Study Reviewing the Effectiveness of Mycophenolate Mofetil on Saudi Children With Nephrotic Syndrome. Cureus. 2023; 15(11): e49679. DOI: 10-7759/cureus.49679.

11. Xiang X., Qiu S-Y., Wang M. Mycophenolate Mofetil in the Treatment of Steroid-Dependent or Frequently Relapsing Nephrotic Syndrome in Children: A Meta-Analysis. Front Pediatr. 2021; 9: 671434. DOI: 10-3389/fped.2021.671434.

12. Hood K.A., Zarembski D.G. Mycophenolate mofetil: a unique immunosuppressive agent. Am J Health Syst Pharm. 1997;54(3):285–294. DOI: 10-1093/ajhp/54.3.285.

13. Golshayan D., Pascual M., Vogt B. Mycophenolic acid formulations in adult renal transplantation — update on efficacy and tolerability. Ther Clin Risk Manag. 2009;5:341–351. DOI: 10-2147/tcrm.s3496.

14. Seyedzadeh A., Tohidi M.R., Rafati M., Seyedzadeh M.S., Hookari S. Mycophenolate Mofetil as a Rescue Therapy in Frequently Relapsing/Steroid-Dependent Nephrotic Syndrome in Children; Ability to Maintain Remission. Iran J Kidney Dis. 2021;15(5):364–372. DOI: 10-52547/ijkd.6376.

15. Gellermann J., Weber L., Pape L., Tönshoff B., Hoyer P., Querfeld U. Mycophenolate Mofetil versus Cyclosporin A in Children with Frequently Relapsing Nephrotic Syndrome. J Am Soc Nephrol. 2013;24(10):1689–1697. DOI: 10-1681/ASN.2012121200.

16. Al-Akash S., Al Makdama A. Mycophenolate mofetil in children with steroid-dependent and/or frequently relapsing nephrotic syndrome. Ann Saudi Med. 2005;25(5):380–384. DOI: 10-5144/0256-4947.2005.380.

17. Ransom J.T. Mechanism of action of mycophenolate mofetil. Ther Drug Monit. 1995;17(6):681–684. DOI: 101097/00007691-199512000-00023.

18. Allison A.C., Eugui E.M. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47(2):85–118. DOI: 10-1016/S0162-3109(00)00188-0.

19. Yu C.C., Yang C.W., Wu M.S., Ko Y.C., Huang C.T., Hong J.J., et al. Mycophenolate mofetil reduces renal cortical inducible nitric oxide synthase mRNA expression and diminishes glomerulosclerosis in MRL/lpr mice. J Lab Clin Med. 2001;138(1):69–77. DOI: 10-1067/mlc.2001.115647.

20. Laurent A.F., Dumont S., Poindron P., Muller C.D. Mycophenolic acid suppresses protein N-linked glycosylation in human monocytes and their adhesion to endothelial cells and to some substrates. Exp Hematol. 1996;24(1):59–67.

21. de Winter B.C.M., van Gelder T., Sombogaard F., Shaw L.M., van Hest R.M., Mathot R.A.A. Genetic and nongenetic determinants of between-patient variability in the pharmacokinetics of mycophenolic acid. Clin Pharmacol Ther. 2005;78(4):317–321. DOI:10,1016/j.clpt.2005.06.008.

22. Rong Y, Jun H, Kiang T. Population pharmacokinetics of mycophenolic acid in paediatric patients. Brit J Clinical Pharma. 2021;87(4):1730–1757. DOI: 10-1111/bcp.14590.

23. Cremers S, Schoemaker R, Scholten E, den Hartigh J, König-Quartel J, van Kan E, et al. Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. Br J Clin Pharmacol. 2005;60(3):249–256. DOI: 10-1111/j.13652125.2005.02398.x.

24. Yoshimura K., Yano I., Yamamoto T., Kawanishi M., Isomoto Y., Yonezawa A., et al. Population pharmacokinetics and pharmacodynamics of mycophenolic acid using the prospective data in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2018;53(1):44–51. DOI: 10-1038/bmt.2017.213.

25. Fromage Y., Sayadi H., Koloskoff K., Marquet P., Labriffe M., Monchaud C., et al. Killing several birds with one stone: A multi-indication population pharmacokinetic model and Bayesian estimator for enteric-coated mycophenolate sodium. BPS Publications. DOI: 10-1111/bcp.16374.

26. Dong M., Fukuda T., Cox S., de Vries M.T., Hooper D.K., Goebel J., et al. Population pharmacokinetic-pharmacodynamic modelling of mycophenolic acid in paediatric renal transplant recipients in the early post-transplant period. Br J Clin Pharmacol. 2014;78(5):1102–1112. DOI: 10-1111/bcp.12426.

27. Tellier S., Dallocchio A., Guigonis V., Saint-Marcoux F., Llanas B., Ichay L., et al. Mycophenolic Acid Pharmacokinetics and Relapse in Children with Steroid–Dependent Idiopathic Nephrotic Syndrome. Clin J Am Soc Nephrol. 2016;11(10):1777–1782. DOI: 10-2215/CJN.00320116.

28. Harambat J, Guigonis V. Reflections on the Use of Mycophenolate Mofetil in Pediatric Nephrotic Syndrome. JAMA Pediatr. 2025;179(10):1133. DOI: 10-1001/jamapediatrics.2025.2710.

29. Sobiak J., Żero P., Zachwieja J., Ostalska-Nowicka D., Pawiński T. Limited sampling strategy to predict free mycophenolic acid area under the concentration-time curve in paediatric patients with nephrotic syndrome. Clin Exp Pharmacol Physiol. 2023;50(6):486–496. DOI: 10-1111/14401681.13765.

30. Benz M.R., Ehren R., Kleinert D., Müller C., Gellermann J., Fehrenbach H., et al. Generation and Validation of a Limited Sampling Strategy to Monitor Mycophenolic Acid Exposure in Children With Nephrotic Syndrome. Therapeutic Drug Monitoring. 2019;(6):696–702. DOI: 10-1097/FTD.0000000000000671.

31. Sobiak J., Resztak M.A. Systematic Review of Multiple Linear Regression-Based Limited Sampling Strategies for Mycophenolic Acid Area Under the Concentration–Time Curve Estimation. Eur J Drug Metab Pharmacokinet. 2021;46(6):721– 742. DOI: 10-1007/s13318-021-00713-0.

32. Sobiak J., Resztak M., Chrzanowska M., Zachwieja J., Ostalska-Nowicka D. The Evaluation of Multiple Linear Regression–Based Limited Sampling Strategies for Mycophenolic Acid in Children with Nephrotic Syndrome. Molecules. 2021;26(12):3723. DOI: 10-3390/molecules26123723.

33. Sharma A.P., Medeiros M., Norozi S., Guzmán-Núñez A.P.M., Filler G. Clinical applicability of 2023 International Pediatric Nephrology Association recommended limited therapeutic drug monitoring formulae to assess mycophenolic acid exposure. Pediatr Nephrol. 2025;40(6):1965–1973. DOI: 101007/s00467-025-06657-w.

34. Filler G., Todorova E.K., Bax K., Alvarez-Elías A.C., Huang S-H.S., Kobrzynski M.C. Minimum mycophenolic acid levels are associated with donor-specific antibody formation. Pediatr Transplant. 2016;20(1):34–38. DOI: 10-1111/petr.12637.

35. Hackl Á., Cseprekál O., Gessner M., Liebau M.C., Habbig S., Ehren R., et al. Mycophenolate Mofetil Therapy in Children With Idiopathic Nephrotic Syndrome: Does Therapeutic Drug Monitoring Make a Difference? Ther Drug Monit. 2016;38(2):274–279. DOI: 10-1097/FTD.0000000000000258.

36. Gellermann J., Ehrich J.H., Querfeld U. Sequential maintenance therapy with cyclosporin A and mycophenolate mofetil for sustained remission of childhood steroid-resistant nephrotic syndrome. Nephrol Dial Transplant. 2012;27(5):1970– 1978. DOI: 10-1093/ndt/gfr572.

37. Sobiak J., Resztak M., Ostalska-Nowicka D., Zachwieja J., Gąsiorowska K., Piechanowska W., et al. Monitoring of mycophenolate mofetil metabolites in children with nephrotic syndrome and the proposed novel target values of pharmacokinetic parameters. Eur J Pharm Sci. 2015; 77: 189–196. DOI: 10-1016/j.ejps.2015.06.017.

38. Morozov S.L., Dlin V.V., Obukhova V.A., Petrosyan E.K., et al. The Importance of Determining the Concentration of Mycophenolic Acid in Children with Steroid-Dependent Nephrotic Syndrome. Rossiyskiy vestnik perinatologii i pediatrii. 2024;69(4):63–69. (in Russ.) DOI:10,21508/10274065-2024-69-4-63-69

39. Sobiak J., Resztak M., Zachwieja J., Ostalska‐Nowicka D. Inosine monophosphate dehydrogenase activity and mycophenolate pharmacokinetics in children with nephrotic syndrome treated with mycophenolate mofetil. Clin Exp Pharma Physio. 2022;49(11):1197–1208. DOI: 101111/1440-1681.13706.

40. Goldsmith D., Carrey E.A., Edbury S., Smolenski R.T., Jagodzinski P., Simmonds H.A. Mycophenolate mofetil, an inhibitor of inosine monophosphate dehydrogenase, causes a paradoxical elevation of GTP in erythrocytes of renal transplant patients. Clin Sci (Lond). 2004;107(1):63–68. DOI: 10-1042/CS20030331.

41. Winnicki W., Fichtenbaum A., Mitulovič G., Herkner H., Regele F., Baier M., et al. Individualization of Mycophenolic Acid Therapy through Pharmacogenetic, Pharmacokinetic and Pharmacodynamic Testing. Biomedicines. 2022;10(11):2882. DOI: 10-3390/biomedicines10112882.

42. Kirpalani A., Rothfels L., Sharma A.P., Cuellar C.R, Filler G. Nephrotic state substantially enhances apparent mycophenolic acid clearance. CN. 2019;91(3):162–171. DOI: 10-5414/CN109583.